Swiss drug developer Roche boosted its hostile tender offer for biotechnology pioneer Genentech Inc. to US$93 per share Friday, raising the total offer value to $45.7 billion, after its initial offer failed to pick up much support from shareholders.
Roche boosts offer for Genentech